Somatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the release of insulin and

Tyr-Somatostatin-14 acetate is a customized peptide that adds a Tyrosine amino acid to Somatostatin-14.

Somatostatin 1-28 acetate circulates in human plasma. Approximately 46% of the total somatostatin-like immunoreactivity in plasma is due to Somatostatin 1-28 acetate.

[D-Trp8,Tyr11] Somatostatin, an analogue of the hormone somatostatin that modulates numerous bodily functions, is characterized by the substitution of DTrp8, which can enhance its stability [1].

(D-Trp8,D-Cys14)-Somatostatin-14, a synthetic analogue of somatostatin, is utilized in the study of metabolic-related diseases [1] [2].

[D-Trp8] Somatostatin-14 is a potent tetradecapeptide analog of native somatostatin, exhibiting increased efficacy [1].

Cyclic somatostatin Acetate(38916-34-6(free base)) (Somatostatin-14) is a cyclic tetradecapeptide regulating many endocrine and nervous system functions.

Somatostatin is an endogenous neuropeptide hormone found in the brain and pancreas. Somatostatin binds several isoforms of the somatostatin receptor, exhibiting anxiolytic, antiepileptic/anticonvulsant, and anorexigenic activities.

[Tyr1]-Somatostatin-14 could binds to SSTR2.

'(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analogue exhibiting varying affinity for somatostatin receptors, with dissociation constants (Kd) of 0.61 nM for SSTR5, 11.05 nM for SSTR3, 23.5 nM for SSTR2, 1200 nM for SSTR1, and >1000 nM for SSTR4, respectively [1].'

Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist utilized in cancer research [1].

Somatostatin acetate is an endogenously secreted inhibitor of cell proliferation with potential antitumor activity for the study of cancer and neurological disorders.

[Nle8] Somatostatin (1-28), a derivative of somatostatin (1-28) with norleucine (Nle) substituting for methionine at position 8, enhances amylase release and elevates cyclic AMP levels in pancreatic acini [1].

[Tyr12] Somatostatin 28 (1-14) is an analogue of the N-terminal fragment [1] of the neuropeptide Somatostatin-28, specifically the first 14 amino acids of the sequence.

Somatostatin receptor agonist, derived from the post-translational cleavage of prosomatostatin.

Cyclic somatostatin (SRIF-14) is a cyclic tetradecapeptide regulating many endocrine and nervous system functions.

[Tyr11]-Somatostatin is a neuroactive peptide utilized in proteomics research. It belongs to a class of neuroactive substances that play a role in modulating retinal physiology.

Somatostatin-28 (1-12) is a somatostatin fragment which is monitored in brain tissue to track processing of somatostatin.

Tyr-Somatostatin-14 is a modified peptide incorporating an additional Tyrosine (amino acid) into the structure of Somatostatin-14.

Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28. Somatostatin 28 arises from the posttranslational cleavage of prosomatostatin, which in turn is derived from a large precursor, preprosomatostatin.

Tyr-Somatostatin-28 is a somatostatin derivative consisting of Somatostatin-28 with an additional Tyrosine amino acid [1].

Cyclosomatostatin Acetate is an effective antagonist of the somatostatin receptor.Cyclosomatostatin Acetate inhibits SSTR1 signaling and decreases cell proliferation, ALDH+ cell population size, and sphere-formation in colorectal cancer cells.

Pasireotide Acetate is a stable cyclohexapeptide somatostatin mimic

CTAP(TFA) (103429-32-9 free base) is a potent, highly selective, and brain-penetrant antagonist of the μ-opioid receptor with IC50 of 3.5 nM. It displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP(TFA） (103429-32-9 free base) can be used for the study of L-DOPA-induced dyskinesia (LID)

Cortistatin-14 acetate, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 acetate shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties

Seglitide acetate (MK-678) is a selective agonist of sst2 somatostatin receptor.

Cortistatin 14, human, rat acetate is a neuropeptide having structural similarity to somatostatin-14 and shows anticonvulsive, neuroprotective effects and remarkable anti-inflammatory properties. Cortistatin 14, human, rat acetate binds and exerts its fun

BIM-23190 aceate, a somatostatin analog, a selective agonist of SSTR2 and SSTR5. BIM-23190 can be used in cancer and acromegaly studies.

CTOP acetate is a somatostatin analogue and a μ-opioid receptor antagonist.

Cyclosomatostatin TFA, a potent somatostatin (SST) receptor antagonist, inhibits type 1 somatostatin receptor (SSTR1) signaling, reducing cell proliferation, the size of the ALDH+ cell population, and sphere-formation in colorectal cancer (CRC) cells [1].

Preprosomatostatin (25-34) is a peptide.

BIM-23027 is a selective sst 2 receptor agonist (EC 50 = 0.32 nM) with effects analogous to the cyclic tetradecapeptide somatostatin (SRIF). It promotes dopamine release through a Glu-dependent mechanism [1] [2].

Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens

Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM. Endogenous peptide with multiple endocrine, metabolic and behavioral effects. Has been shown to have an action on intestinal

Nendratareotide is a somatostatin analogue.

Veldoreotide, also known as Somatoprim, is a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue which effectively reduces GH secretion in human GH-secreting pituitary adenomas, even in Octreotide non-responsive tumours.

PACAP (1-38) free acid TFA, an endogenous neuropeptide, effectively enhances antral motility and somatostatin secretion, while concurrently suppressing gastrin secretion and promoting the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P. Additionally, it amplifies N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1 [1] [2].

PACAP (1-38) free acid, an endogenous neuropeptide, potently modulates gastrointestinal and neuroendocrine functions. It enhances antral motility, increases somatostatin secretion, and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P, while concurrently inhibiting gastrin secretion. Additionally, it augments N-methyl-D-aspartate receptor function and upregulates brain-derived neurotrophic factor expression via RACK1 [1] [2].

Wy 41747 is a long-acting somatostatin analogue utilized in research of diabetes mellitus [1].

Potent and selective μ opioid receptor antagonist (IC50 = 3.5 nM). Displays > 1200-fold selectivity over δ opioid and somatostatin receptors. Brain penetrant and active in vivo.

Pasireotide(SOM 230) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively).

Cortistatin-14 is a neuropeptide have structural similarity to somatostatin-14. It is produced in the cortex and hippocampus of central nervous system.

DOTA-JR11 is a somatostatin receptor 2 (SSTR2) antagonist that can be radiolabeled with 68Ga. It is utilized for paired imaging in the study of neuroendocrine tumors (NETs) [1].

RC-160 [Lys(Boc)], an 8-amino acid peptide, functions as a somatostatin analog [1].

Peptide agonist for sst2 and sst5 somatostatin receptors. IC50/Kd values (nM) at cloned human somatostatin receptors are: > 1000 (sst1), 0.2 - 1.5 (sst2), 27 - 36 (sst3), > 127 (sst4), and 0.06 - 23 (sst5).

Lanreotide (BIM 23014) diTFA, a somatostatin analogue, exhibits antineoplastic activity and may be utilized in carcinoid syndrome research [1] [2].

PEN-221 is a Somatostatin receptor 2 (SSTR2)-targeting cytotoxic conjugate with an IC50 of 10 nM. PEN-221 is a conjugate consisting of microtubule-targeting agent DM1 linked to the C-terminal side chain of Tyr3-octreotate.

Onzigolide (BIM-23A760), a chimeric compound combining properties of both dopamine and somatostatin, exhibits strong agonistic activity towards the D2 subtype of dopamine receptors (D2R) as well as type 2 somatostatin receptors (SSTR2).

CTAP TFA, a potent and highly selective μ opioid receptor antagonist that effectively crosses the blood-brain barrier, exhibits a significant inhibition concentration (IC50) of 3.5 nM. It demonstrates extraordinary selectivity, being over 1200-fold more specific to μ opioid receptors than to δ opioid (IC50 = 4500 nM) and somatostatin receptors. This compound is primarily leveraged for researching L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction [1] [2].

sst1/sst4 somatostatin receptors agonist